A recent study in 44 adult B-ALL patients suggested that the intrinsic characteristics of tumors, like CD19 loss, may be responsible for blinatumomab resistance [61]. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.